Rocket Pharmaceuticals Stock Return On Equity

RCKT Stock  USD 9.36  0.69  6.87%   
Rocket Pharmaceuticals fundamentals help investors to digest information that contributes to Rocket Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Rocket Stock. The fundamental analysis module provides a way to measure Rocket Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Rocket Pharmaceuticals stock.
Last ReportedProjected for Next Year
Return On Equity(0.57)(0.60)
Return On Equity is likely to drop to -0.6 in 2025.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Rocket Pharmaceuticals Company Return On Equity Analysis

Rocket Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Return On Equity

 = 

Net Income

Total Equity

More About Return On Equity | All Equity Analysis

Current Rocket Pharmaceuticals Return On Equity

    
  -0.59  
Most of Rocket Pharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Rocket Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Rocket Return On Equity Driver Correlations

Understanding the fundamental principles of building solid financial models for Rocket Pharmaceuticals is extremely important. It helps to project a fair market value of Rocket Stock properly, considering its historical fundamentals such as Return On Equity. Since Rocket Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Rocket Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Rocket Pharmaceuticals' interrelated accounts and indicators.
1.0-0.57-0.56-0.850.230.660.920.560.970.940.63-0.10.920.870.89-0.960.970.950.610.85
1.0-0.57-0.57-0.850.250.620.930.560.970.940.61-0.140.910.870.9-0.960.960.950.610.85
-0.57-0.570.090.71-0.86-0.33-0.45-0.3-0.6-0.5-0.250.0-0.59-0.61-0.690.59-0.56-0.45-0.84-0.68
-0.56-0.570.090.15-0.18-0.26-0.73-0.64-0.41-0.72-0.350.05-0.21-0.54-0.290.54-0.62-0.720.2-0.2
-0.85-0.850.710.15-0.28-0.52-0.7-0.34-0.89-0.73-0.460.12-0.93-0.83-0.940.84-0.8-0.71-0.85-0.94
0.230.25-0.86-0.18-0.280.080.220.240.220.260.110.060.140.330.31-0.260.260.180.480.27
0.660.62-0.33-0.26-0.520.080.680.420.590.630.650.470.640.60.48-0.640.70.690.370.61
0.920.93-0.45-0.73-0.70.220.680.590.861.00.670.010.750.890.73-0.90.950.960.370.77
0.560.56-0.3-0.64-0.340.240.420.590.390.580.060.210.40.650.41-0.630.660.720.130.41
0.970.97-0.6-0.41-0.890.220.590.860.390.880.61-0.190.960.820.92-0.930.910.870.710.88
0.940.94-0.5-0.72-0.730.260.631.00.580.880.64-0.030.770.910.78-0.920.960.960.420.79
0.630.61-0.25-0.35-0.460.110.650.670.060.610.640.190.510.450.45-0.520.550.550.240.42
-0.1-0.140.00.050.120.060.470.010.21-0.19-0.030.19-0.110.1-0.08-0.010.050.05-0.15-0.01
0.920.91-0.59-0.21-0.930.140.640.750.40.960.770.51-0.110.790.92-0.890.860.80.790.91
0.870.87-0.61-0.54-0.830.330.60.890.650.820.910.450.10.790.85-0.920.940.890.550.91
0.890.9-0.69-0.29-0.940.310.480.730.410.920.780.45-0.080.920.85-0.890.850.790.780.91
-0.96-0.960.590.540.84-0.26-0.64-0.9-0.63-0.93-0.92-0.52-0.01-0.89-0.92-0.89-0.97-0.94-0.62-0.88
0.970.96-0.56-0.62-0.80.260.70.950.660.910.960.550.050.860.940.85-0.970.980.540.87
0.950.95-0.45-0.72-0.710.180.690.960.720.870.960.550.050.80.890.79-0.940.980.40.77
0.610.61-0.840.2-0.850.480.370.370.130.710.420.24-0.150.790.550.78-0.620.540.40.8
0.850.85-0.68-0.2-0.940.270.610.770.410.880.790.42-0.010.910.910.91-0.880.870.770.8
Click cells to compare fundamentals
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Competition

Rocket Total Stockholder Equity

Total Stockholder Equity

594.78 Million

At this time, Rocket Pharmaceuticals' Total Stockholder Equity is comparatively stable compared to the past year.
Based on the latest financial disclosure, Rocket Pharmaceuticals has a Return On Equity of -0.5927. This is 97.53% lower than that of the Biotechnology sector and 98.37% lower than that of the Health Care industry. The return on equity for all United States stocks is 91.19% higher than that of the company.

Rocket Return On Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Rocket Pharmaceuticals' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Rocket Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Rocket Pharmaceuticals by comparing valuation metrics of similar companies.
-0.5927-0.1784-0.2106-0.3984-0.4450100%
Rocket Pharmaceuticals is currently under evaluation in return on equity category among its peers.

Rocket Pharmaceuticals Current Valuation Drivers

We derive many important indicators used in calculating different scores of Rocket Pharmaceuticals from analyzing Rocket Pharmaceuticals' financial statements. These drivers represent accounts that assess Rocket Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Rocket Pharmaceuticals' important valuation drivers and their relationship over time.
202020212022202320242025 (projected)
Market Cap3.0B1.4B1.3B2.5B2.3B2.4B
Enterprise Value2.8B1.2B1.2B2.5B2.2B2.4B

Rocket Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Rocket Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Rocket Pharmaceuticals' managers, analysts, and investors.
69.4%
Environmental
61.7%
Governance
Social

Rocket Fundamentals

Return On Equity-0.59
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-400%-300%-200%-100%
Return On Asset-0.34
Current Valuation903.33 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%500%1,000%1,500%2,000%
Shares Outstanding106.34 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-311,000%2,000%3,000%4,000%
Shares Owned By Insiders2.92 %
Shares Owned By Institutions97.08 %
Number Of Shares Shorted10.52 M
Price To Book3.38 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-400%-300%-200%-100%
EBITDA(236.62 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-311,000%2,000%3,000%4,000%
Net Income(245.59 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-311,000%2,000%3,000%4,000%
Cash And Equivalents321.37 M
Cash Per Share4.87 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31500%1,000%1,500%2,000%2,500%3,000%3,500%
Total Debt25.04 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%500%1,000%1,500%2,000%
Debt To Equity0.06 %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-1,200%-1,000%-800%-600%-400%-200%0%
Current Ratio13.41 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-311,000%2,000%3,000%4,000%5,000%6,000%7,000%
Book Value Per Share3.62 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-250%-200%-150%-100%-50%0%
Cash Flow From Operations(194.92 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%500%1,000%1,500%2,000%2,500%
Short Ratio6.37 X
Earnings Per Share(2.73) X
Price To Earnings To Growth0.03 X
Target Price43.07
Number Of Employees268
Beta0.98
Market Capitalization1.07 B
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%500%1,000%
Total Asset566.34 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-3110,000%20,000%30,000%40,000%
Retained Earnings(959.37 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%100%200%300%400%500%600%700%
Working Capital329.72 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Net Asset566.34 M

About Rocket Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Rocket Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rocket Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rocket Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Rocket Stock Analysis

When running Rocket Pharmaceuticals' price analysis, check to measure Rocket Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rocket Pharmaceuticals is operating at the current time. Most of Rocket Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Rocket Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rocket Pharmaceuticals' price. Additionally, you may evaluate how the addition of Rocket Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.